786666-07-7

Basic information

• Product Name: 3-amino-5-(6-(3-iodobenzylamino)purin-9-yl)-4-t-butyldimethylsiloxy-tetrahydro-furan-2-carboxylic acid methyl amide
• Synonyms: 3-amino-5-(6-(3-iodobenzylamino)purin-9-yl)-4-t-butyldimethylsiloxy-tetrahydro-furan-2-carboxylic acid methyl amide
• CAS NO: 786666-07-7
• Molecular Weight: 623.569
• Mol File: 786666-07-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-amino-5-(6-(3-iodobenzylamino)purin-9-yl)-4-t-butyldimethylsiloxy-tetrahydro-furan-2-carboxylic acid methyl amide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-5-(6-(3-iodobenzylamino)purin-9-yl)-4-t-butyldimethylsiloxy-tetrahydro-furan-2-carboxylic acid methyl amide(786666-07-7)
• EPA Substance Registry System: 3-amino-5-(6-(3-iodobenzylamino)purin-9-yl)-4-t-butyldimethylsiloxy-tetrahydro-furan-2-carboxylic acid methyl amide(786666-07-7)

Safety Data

• Hazardous Substances Data: 786666-07-7(Hazardous Substances Data)

Upstream product

• 786666-03-3 3-azido-5-(6-(3-iodobenzylamino)purin-9-yl)-4-t-butyldimethylsiloxy-tetrahydro-furan-2-carboxylic acid methyl amide 
• 35085-25-7 3-azido-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose 
• 21870-78-0 3-azido-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-allofuranose 
• 55951-93-4 1,2:5,6-di-O-isopropylidene-3-O-triflyl-α-D-glucofuranose 
• 86945-40-6 3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranuronic acid 
• 582-52-5 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 786665-99-4 (2S,3S,4R,5R) 3-azido-4-hydroxy-5-(6-[3-iodobenzylamino]-purin-9-yl)-tetrahydro-furan-2-carboxylic acid methylamide 
• 331729-03-4 (2S,3S,4R,5R)-3-azido-5-(6-chloro-purin-9-yl)-4-acetoxy-tetrahydro-furan-2-carboxylic acid methylamide 
• 331729-04-5 3-azido-3-deoxy-1,2-diacetoxy-α-D-ribofuranuronic acid methyl amide 
• 331729-05-6 3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranuronic acid methyl amide 

Downstream Products

• 786666-15-7 3-ureido-5-(6-(3-iodobenzylamino)purin-9-yl)-4-t-butyldimethylsiloxy-tetrahydro-furan-2-carboxylic acid methyl amide 

Relevant articles and documents

Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists

An alternative approach to overcome the inherent lack of specificity of conventional agonist therapy can be the reengineering of the GPCRs and their agonists. A reengineered receptor (neoceptor) could be selectively activated by a modified agonist, but no